17,261 trials
Psoriasis, Plaque-type Psoriasis
Primary: Percentage of Participants Achieving Skin Histology Response After Secukinumab Treatment From Baseline to Week 12 — 56.5; 0.0 percentage of participants — p=<0.001
Myelodysplastic Syndromes
Primary: Number of Participants With Confirmed Responses (Complete Remission, Partial Remission, or Hematologic Improvement) as Defined by the International Working Group…
Breast Cancer
Primary: Percentage of Participants With Pathological Complete Response. — 41 percentage of evaluable patients
Adult T-Cell Leukemia-Lymphoma
Primary: Percentage of Participants Who Achieved a Complete Response, Unconfirmed Complete Response, or Partial Response as Assessed by the Efficacy-Safety Evaluation Committee…
Hypertension
Primary: Change in Blood Pressure After Intrathecal Injection of Clonidine. — 79; 37 mm Hg
Alzheimer Disease
Primary: Incidence of Treatment-emergent Adverse Events (AEs) by Severity — 5; 6; 4; 5 Participants
Alzheimer Disease
Primary: Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs) — 97.2; 93.3; 90.0; 91.4 percentage of participants
Chronic Renal Failure
Primary: Change in Daily Urine Volume From Baseline — 18.3 mL
Alzheimer Disease
Primary: Percentage of Participants With Treatment-emergent AEs or Serious Adverse Events (SAEs) — 97.2; 93.3; 90.0; 91.4 percentage of participants
Marginal Zone Lymphoma
Primary: Overall Rate of Response (ORR) in Participants Receiving Protocol Therapy. — 87.5 percentage of participants
Alzheimer's Disease
Primary: Incidence of Treatment-emergent Adverse Events (AEs) by Severity — 4; 7; 7; 5 Participants
Peripheral Arterial Disease
Primary: Change in Exercise Capacity: VO2peak (Maximal Oxygen Consumption) — 1.48; 0.23 ml/kg/min
Solid Tumor · Anaplastic Thyroid Cancer
Primary: Maximum Tolerated Dose (MTD) of Cisplatin (Phase I) — 100 mg/m^2
Amyotrophic Lateral Sclerosis
Primary: ALSFRS-R Total Score at Weeks 0, 2, 4 and 8 — 38.60; 38.60; 38.15; 38.29 scores on a scale — p=0.780
Lymphoma
Primary: Objective Response Rate — .25 proportion of participants